CHROMATOGRAPHIC AND COMPUTATIONAL APPROACHES TO THE PHARMACOKINETIC PROFILE OF PIROXICAM AND ITS SENSITIVE ASSAY IN RABBIT PLASMA

Öz

Objective: A simple, rapid, sensitive, and cost-effective high-performance liquid chromatographic (HPLC) method was developed for the pharmacokinetic study and determination of Piroxicam.

Material and Method: The chromatographic separation was performed with a Agilent ZORBAX reversed-phase C18 column (250 mm × 4,6 mm ID × 5 μm). Mobile phase composition was 0.04 M KH₂PO₄: acetonitrile:methanol (50:40:10) at pH 3.8. The flow rate was adjusted as 0.9 mL/min.

Result and Discussion: An isocratic method was used for the analysis. The UV detector was set at 360 nm, and a retention time of 7 minutes was obtained for piroxicam. The method showed linear performance over the concentration range of 0.1–4 mg/l.

Anahtar Kelimeler

• ADMET
• chromatography
• DFT calculation
• pharmacokinetic analysis
• piroxicam

Tavşan plazmasında piroksikamın farmakokinetik profiline ve hassas analizine yönelik kromatografik ve hesaplamalı yaklaşımlar

Öz

Amaç: Piroksikam’ın farmakokinetik çalışması ve tayini için basit, hızlı, hassas ve maliyet etkin bir yüksek performanslı sıvı kromatografi (HPLC) yöntemi geliştirilmiştir.

Gereç ve Yöntem: Kromatografik ayrım, Agilent ZORBAX ters fazlı C18 kolon (250 mm × 4,6 mm ID × 5 μm) kullanılarak gerçekleştirilmiştir. Mobil faz bileşimi, pH 3.8’de 0.04 M KH₂PO₄:asetonitril:metanol (50:40:10) oranında hazırlanmıştır. Akış hızı 0.9 ml/dk olarak ayarlanmıştır.

Sonuç ve Tartışma: Analiz için izokratik yöntem kullanılmıştır. UV dedektörü 360 nm’ye ayarlanmış ve piroksikam için 7 dakikalık bir alıkonma süresi elde edilmiştir. Yöntem, 0.1–4 mg/l konsantrasyon aralığında doğrusal performans göstermiştir.

Anahtar Kelimeler

• ADMET
• DFT hesaplaması
• farmakokinetik analiz
• kromatografi
• piroksikam

Kaynakça

1. 1. Starek, M., Krzek, J. (2009). A review of analytical techniques for determination of oxicams, nimesulide and nabumetone. Talanta, 77, 925-942. [CrossRef]
2. 2. Macià, A., Borrull, F., Calull, M., et al. (2007). Capillary electrophoresis for the analysis of non-steroidal anti-inflammatory drugs. TrAC Trends in Analytical Chemistry, 26, 133-153. [CrossRef]
3. 3. Arancibia, J.A., Escandar, G.M. (2003). Two different strategies for the fluorimetric determination of piroxicam in serum. Talanta, 6, 1113-1121. [CrossRef]
4. 4. Ramesh, K.C., Gowda B.G., Seetharamappa J., et al. (2003). Indirect spectrofluorimetric determination of piroxicam and propranolol hydrochloride in bulk and pharmaceutical preparations. Journal of Analytical Chemistry, 58, 933-936. [CrossRef]
5. 5. Amin, A.S. (2002). Spectrophotometric determination of piroxicam and tenoxicam in pharmaceutical formulations using alizarin. Journal of Pharmaceutical and Biomedical Analysis, 29, 729-736. [CrossRef]
6. 6. Basan, H., Göğer N.G., Ertaş N., et al. (2001). Quantitative determination of piroxicam in a new formulation (piroxicam-beta-cyclodextrin) by derivative UV spectrophotometric method and HPLC. Journal of Pharmaceutical and Biomedical Analysis, 26, 171-178. [CrossRef]
7. 7. Bartsch, H., Eiper A., Kopelent-Frank, H. (1999). Stability indicating assays for the determination of piroxicam-comparison of methods. Journal of Pharmaceutical and Biomedical Analysis, 20, 531-541. [CrossRef]
8. 8. Crecelius, A., Clench, M.R., Richards, D.S., et al. (2004). Quantitative determination of piroxicam by TLC-MALDI TOF MS. Journal of Pharmaceutical and Biomedical Analysis, 35, 31-39. [CrossRef]

9. 9. Chen, Y.L., Wu, S.M. (2005). Capillary zone electrophoresis for simultaneous determination of seven nonsteroidal anti-inflammatory drugs in pharmaceuticals. Analytical and Bioanalytical Chemistry, 381, 907-912. [CrossRef]
10. 10. Donato, M.G., Baeyens, W., Bossche, W.V.D. (1994). The determination of non-steroidal antiinflammatory drugs in pharmaceuticals by capillary zone electrophoresis and micellar electrokinetic capillary chromatography. Journal of Pharmaceutical and Biomedical Analysis, 12, 21-26. [CrossRef]
11. 11. Amanlou, M., Dehpour, A.R. (1997). Rapid method for the determination of piroxicam in rat plasma using high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications, 696, 317-319. [CrossRef]
12. 12. De Jager, A.D., Ellis, H., Hundt, H.K.L., et al. (1999). High-performance liquid chromatographic determination with amperometric detection of piroxicam in human plasma and tissues. Journal of Chromatography B: Biomedical Sciences and Applications, 729, 183-189. [CrossRef]
13. 13. Yritia, M., Parra, P., Fernandez, J.M., et al. (1999). Piroxicam quantitation in human plasma by high-performance liquid chromatography with on- and off-line solid-phase extraction. Journal of Chromatography A. 846, 199-205. [CrossRef]
14. 14. Hye, Y.J., Lee, H.W., Kim, G.H., et al. (2005). Simultaneous determination of piroxicam, meloxicam and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 826, 214-219. [CrossRef]
15. 15. Dadashzadeh, S., Vali, A.M., Rezagholi, N. (2002). LC determination of piroxicam in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 28, 1201-1204. [CrossRef]
16. 16. Doliwa, A., Santayo, S., Campanero, M.A., et al. (2001). Sensitive LC determination of piroxicam after in vitro transdermal permeation studies. Journal of Pharmaceutical and Biomedical Analysis, 26, 531-537. [CrossRef]
17. 17. Song, X.Y., Shi Y.P., Chen J. (2012). A novel extraction technique based on carbon nanotubes reinforced hollow fiber solid/liquid microextraction for the measurement of piroxicam and diclofenac combined with high performance liquid chromatography. Talanta, 100, 153-156. [CrossRef]
18. 18. Shirako, J., Kawasaki, M., Komine, K., et al. (2013). Simultaneous determination for oxicam non-steroidal anti-inflammatory drugs in human serum by liquid chromatography-tandem mass spectrometry. Forensic Science International, 227, 100-102. [CrossRef]
19. 19. Dowling, G., Malone, E. (2011). Analytical strategy for the confirmatory analysis of the non-steroidal anti-inflammatory drugs firocoxib, propyphenazone, ramifenazone and piroxicam in bovine plasma by liquid chromatography tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 56, 359-365. [CrossRef]
20. 20. Caldwell, G., Yan Z., Tang, W., et al. (2009). ADME optimization and toxicity assessment in early- and late-phase drug discovery. Current Topics in Medicinal Chemistry, 9, 965-980. [CrossRef]
21. 21. Patel, N., Jain, Ş., Lin S., et al. (2016). Transdermal iontophoretic delivery of tacrine hydrochloride: Correlation between in vitro permeation and in vivo performance in rats. International Journal of Pharmaceutics, 513, 393-403. [CrossRef]
22. 22. Ferreira, L.L.G., Andricopulo, A.D. (2019). ADMET modeling approaches in drug discovery. Drug Discovery Today, 24, 1157-1165. [CrossRef]
23. 23. International Conference on Harmonization (ICH), Harmonised Tripartite Guideline. (1994) Text on validation of analytical procedures. Geneva. p. 1-5. [CrossRef]
24. 24. Frisch, M.J., Trucks, G.W., Schlegel, H.B., et al. (2009). https://gaussian.com/g09citation/. Accessed date: 21.08.2025.
25. 25. Accelrys Software Inc. (2013). https://www.rdworldonline.com/accelrys-discovery-studio-3-5/. Accessed date: 21.08.2025.
26. 26. Lipinski, C.A., Lambardo, F., Dominy, B.W., et al. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23, 3-25. [CrossRef]
27. 27. Veber, D.F., Johnson, S.R., Cheng, H.Y., et al. (2002). Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry, 45(12), 2615-2623.[CrossRef]
28. 28. Sander, T., Freyss, J., Korff, M., et al. (2015). DataWarrior: An open-source program for chemistry aware data visualization and analysis. Journal of Chemical Information and Modeling, 55(2), 460-473. [CrossRef]
29. 29. Hemelryck, S.V., Dewulf, J., Niekus, H., et al. (2019). In vitro evaluation of poloxamer in situ forming gels for bedaquiline fumarate salt and pharmacokinetics following intramuscular injection in rats. International Journal of Pharmaceutics X, 1, 100016. [CrossRef]
30. 30. Zhang, Y., Huo M., Zhou J., et al. (2010). PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Computer Methods and Programs in Biomedicine, 3, 306-314. [CrossRef]
31. 31. Xuan, J.J., Balakrishnan P., Oh, D.H., et al. (2010). Rheological characterization and in vivo evaluation of thermosensitive poloxamer-based hydrogel for intramuscular injection of piroxicam. International Journal of Pharmaceutics, 395, 317-323. [CrossRef]